Literature DB >> 31409922

In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab.

Djordje Atanackovic1, Sara Yousef2,3, Christa Shorter2, Srinivas K Tantravahi2, Mary Steinbach2, Fiorella Iglesias4, Douglas Sborov2, Sabarinath Venniyil Radhakrishnan2, Marielle Chiron5, Rodney Miles6, Mohamed Salama6, Nicolaus Kröger3, Tim Luetkens2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31409922     DOI： 10.1038/s41375-019-0536-3

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  17 in total

1.  Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma.

Authors:  Meletios Dimopoulos; Sara Bringhen; Pekka Anttila; Marcelo Capra; Michele Cavo; Craig Cole; Cristina Gasparetto; Vania Hungria; Matthew Jenner; Vladimir Vorobyev; Eduardo Yanez Ruiz; Jian Y Yin; Rao Saleem; Maeva Hellet; Sandrine Macé; Bruno Paiva; Ravi Vij
Journal:  Blood       Date:  2021-03-04       Impact factor: 22.113

Review 2.  Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy.

Authors:  Ewelina Grywalska; Barbara Sosnowska-Pasiarska; Jolanta Smok-Kalwat; Marcin Pasiarski; Paulina Niedźwiedzka-Rystwej; Jacek Roliński
Journal:  Cells       Date:  2020-04-16       Impact factor: 6.600

Review 3.  Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.

Authors:  Thomas G Martin; Kathryn Corzo; Marielle Chiron; Helgi van de Velde; Giovanni Abbadessa; Frank Campana; Malini Solanki; Robin Meng; Helen Lee; Dmitri Wiederschain; Chen Zhu; Alexey Rak; Kenneth C Anderson
Journal:  Cells       Date:  2019-11-26       Impact factor: 6.600

4.  Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19.

Authors:  Tim Luetkens; Ryan Metcalf; Vicente Planelles; Yue Zheng; Erin T Larragoite; Emily S Spivak; Adam M Spivak; Mary Steinbach; Robert C Blaylock; Stephanie V Avila; Kim G Hankey; Thomas B Martins; Patricia R Slev; Heather D Mannuel; Mohammad Sajadi; Aaron P Rapoport; Djordje Atanackovic
Journal:  Blood Adv       Date:  2020-10-13

5.  Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Authors:  Paul G Richardson; Thierry Facon; William I Bensinger; Xavier Leleu; Frank Campana; Sandrine Macé; Marielle Chiron; Helgi van de Velde; Joseph Mikhael
Journal:  Blood Cancer J       Date:  2021-03-12       Impact factor: 11.037

6.  Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.

Authors:  Chen Zhu; Zhili Song; Anlai Wang; Srimathi Srinivasan; Guang Yang; Rita Greco; Joachim Theilhaber; Elvis Shehu; Lan Wu; Zhi-Yong Yang; Wilfried Passe-Coutrin; Alain Fournier; Yu-Tzu Tai; Kenneth C Anderson; Dmitri Wiederschain; Keith Bahjat; Francisco J Adrián; Marielle Chiron
Journal:  Front Immunol       Date:  2020-08-14       Impact factor: 7.561

Review 7.  CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults.

Authors:  Francesco Lanza; Enrico Maffini; Michela Rondoni; Evita Massari; Angelo Corso Faini; Fabio Malavasi
Journal:  Cancers (Basel)       Date:  2020-01-28       Impact factor: 6.639

Review 8.  The Circular Life of Human CD38: From Basic Science to Clinics and Back.

Authors:  Alberto L Horenstein; Angelo C Faini; Fabio Morandi; Cristiano Bracci; Francesco Lanza; Nicola Giuliani; Aneel Paulus; Fabio Malavasi
Journal:  Molecules       Date:  2020-10-21       Impact factor: 4.411

9.  Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting.

Authors:  Domenico Viola; Ada Dona; Enrico Caserta; Estelle Troadec; Francesca Besi; Tinisha McDonald; Lucy Ghoda; Emine Gulsen Gunes; James F Sanchez; Jihane Khalife; Marianna Martella; Chatchada Karanes; Myo Htut; Xiuli Wang; Michael Rosenzweig; Arnab Chowdhury; Douglas Sborov; Rodney R Miles; Paul J Yazaki; Todd Ebner; Craig C Hofmeister; Stephen J Forman; Steven T Rosen; Guido Marcucci; John Shively; Jonathan J Keats; Amrita Krishnan; Flavia Pichiorri
Journal:  Leukemia       Date:  2020-04-16       Impact factor: 11.528

Review 10.  Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.

Authors:  Giovanni Palladini; Paolo Milani; Fabio Malavasi; Giampaolo Merlini
Journal:  Cells       Date:  2021-03-04       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.